Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
Abstract Background Peptide receptor radionuclide therapy (PRRT) with [177Lu]-DOTA-TATE is an effective treatment of neuroendocrine tumors (NETs). After each cycle of treatment, patient dosimetry evaluates the radiation dose to the risk organs, kidneys, and bone marrow, the most radiosensitive tissu...
Main Authors: | Alexandre Chicheportiche, Faozi Artoul, Arnon Schwartz, Simona Grozinsky-Glasberg, Amichay Meirovitz, David J. Gross, Jeremy Godefroy |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2018-06-01
|
Series: | EJNMMI Physics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40658-018-0211-1 |
Similar Items
-
Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
by: Alexandre Chicheportiche, et al.
Published: (2020-01-01) -
Peptide Receptor Radionuclide Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
by: Maria I. del Olmo-García, et al.
Published: (2022-01-01) -
PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
by: Alexander R. Haug
Published: (2020-04-01) -
Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
by: Frederik A. Verburg, et al.
Published: (2023-11-01) -
Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
by: Sejin Ha, et al.
Published: (2024-02-01)